Vendor Intelligence Report: Noble Dragons

Published 13 Jun 2026. 19-page investigative report on who is behind Noble Dragons: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 18 Finnrick lab tests, Noble Dragons posts 15 pass / 3 fail, an 83% overall pass rate. The dataset is narrow but directional: tirzepatide is the stronger visible line, while retatrutide is weaker and includes a severe fill-accuracy event that makes current-batch verification essential. Ratings are methodology-sensitive when fill accuracy is weighted, so a purity-looking score should not be read as a complete injectable-safety verdict.

The accountability trail points east, not to a familiar Western wrapper. The peptide shop sits on buy.nobledragons.com while the root domain was observed as tea or beverage content; separate COA and FAQ subdomains complete the operating surface. Noble Dragons' own terms point to Taizhou, Jiangsu, China, PRC law, CIETAC arbitration, and China-origin shipping, and registry searches did not confirm a Delaware, U.K., or OpenCorporates entity.

HJH-series batch IDs and no-label silver-crimp containers align with ABC Allen-style records, supporting a reseller or shared-source model rather than a transparent manufacturer-disclosed supply chain. Gray Guide and PRG also route buyers toward Alex Wu/Noble Dragons through a Mr Fox-branded funnel; common control remains unresolved, but the independence of the guide is not verifiable from public records.

The safety and delivery risks are separate from product identity. Most Finnrick-tested samples lack endotoxin data, and the Noble Dragons Janoshik COA program covers purity and mass rather than endotoxins. U.S. buyers also sit in an active customs lane: Noble Dragons says orders ship from China and disclaims seizure responsibility, while CBP has reported large seizures of similar China-origin peptide categories.

Inside the full report:

  • Appendix A Finnrick lab table and methodology-divergence charts for both tested products
  • Retatrutide underfill exhibit with batch-level dosing interpretation
  • ABC Allen-style batch-ID and silver-crimp packaging provenance comparison
  • Domain/legal review: root, buy, COA, FAQ, PRC terms, and registry dead ends
  • Gray Guide/PRG funnel analysis, endotoxin-COA gap, and CBP seizure-risk review

Risk assessment

  • Supply-chain provenance risk — high: Batch IDs/container format indicate shared sourcing with ABC Allen, an E-rated upstream in field review; consumers cannot independently trace current upstream source.
  • Endotoxin-testing gap — high: For Retatrutide and Tirzepatide, 15 of 18 Finnrick-tested samples lacked endotoxin data; the Noble Dragons COA program tests purity/mass but not endotoxins.
  • China-to-U.S. import seizure risk — high: Terms state orders ship from China and disclaim customs responsibility; CBP seized over 5,000 similar Chinese peptide shipments including retatrutide, tirzepatide and semaglutide.
  • Retatrutide fill-accuracy risk — medium: Retatrutide has 7 pass / 3 fail across 10 tests, including a March 18, 2026 vial underfilled by -57.5% at 8.5 mg in a 20 mg vial; Tirzepatide is stronger at 8/8 pass.
  • Community-funnel transparency risk — medium: Gray Guide/PRG presents Noble Dragons/Alex Wu as a primary verified vendor while operator identity is pseudonymous and forum users allege sourcing questions are suppressed.